Human Gut Atlas

The most comprehensive cell map of the human gut to date has been created by combining spatial and single-cell data from 1.6 million cells.

Mapping the cells of the gut can provide us with further insights into what happens in conditions such as bowel cancer and Inflammatory Bowel Disease (IBD). Using this atlas, researchers from the Wellcome Sanger Institute and collaborators uncovered a new role of a specific gut cell, highlighting its contributions to a cycle of inflammation in some individuals, possibly causing pain and distress.

IBD gut tissue

The study, published today (20 November) in Nature, details how the team harmonised over 25 single-cell datasets of the human gastrointestinal (GI) tract to create the world’s largest freely-available resource of the human gut to date. This includes samples from those with health conditions as well as those without.

By having a more complete picture of the human gut in health and disease, researchers can identify any key changes or differences that could be involved in the onset of conditions such as ulcerative colitis and Crohn’s disease, and lead to new possible targets for drug development.

This paper is one of a collection of more than 40 Human Cell Atlas publications in Nature Portfolio journals that represent a milestone leap in our understanding of the human body. These highly complementary studies have shed light on central aspects of human development, and health and disease biology, and have led to the development of vital analytical tools and technologies, all of which will contribute to the creation of the Human Cell Atlas.1

The GI tract is the general name for a group of organs involved in the digestive system that work together to absorb nutrients from our food and act as a barrier against pathogens. It starts at the mouth and includes the throat, oesophagus, stomach, small intestine, large intestine, rectum, and anus.

GI tract conditions impact millions of lives around the world. For example, ulcerative colitis and Crohn’s disease, which are both types of IBD, affect over seven million people worldwide,2 with one in every 123 people in the UK living with IBD.3 IBD symptoms can vary between people and have a huge impact on a person’s life. These include abdominal pain, diarrhoea, rectal bleeding, extreme fatigue and joint problems.4

Bowel cancer, also known as colorectal cancer, starts in the large intestine and is the fourth most common cancer in the UK, with almost 43,000 people diagnosed every year.5 Globally, there are around two million cases,6 and it is estimated that one in 17 men and one in 20 women will be diagnosed with bowel cancer during their lifetime.5

Due to the impact of these conditions, there have been multiple single-cell studies investigating the cellular structure of the GI tract in health and disease. These studies have separate processes and labelling systems, which can create difficulties when external researchers attempt to use them.

In this latest study, researchers from the Wellcome Sanger Institute and collaborators developed a new tool to harmonise these data, creating a standardised resource of gut cells that is available to researchers worldwide. This tool could also be applied to other organs, and help facilitate further studies.

The team merged 25 datasets, resulting in an atlas of 1.6 million cells containing both single-cell and spatial data, allowing researchers to see what cells were present, where they were located, and how they communicated with the environment around them. The atlas was created with data from tissue samples from those without GI issues, as well as those with gastric and colorectal cancers, coeliac disease, ulcerative colitis, and Crohn’s disease.

The team also identified a type of gut cell that may have a role in inflammation. The cells, known as gut metaplastic cells, are known to be involved in healing the stomach lining. However, the team discovered that these cells contained genetic similarities to other GI cells involved in inflammation. They suggest that inflammation in IBD leads to changes in these metaplastic cells, which actively contributes to further inflammatory responses.

By understanding more about this cycle of inflammation, it might be possible to find new ways to prevent or treat this in IBD and possibly apply this knowledge to other tissues and conditions.

“Spatial and single-cell data provide unique information about how gut cells interact, that can be used to continue piecing together an in-depth understanding of how the human body works. Combining existing single-cell datasets allows us to create a more complete picture of the human gut and ensures that researchers can work together to continue to benefit human health. Our Gut Cell Atlas is also harmonized and freely available, and we hope that people will continue to build on this, adding in data for scientists worldwide to use.” - Amanda Oliver
“As the integrated atlas contains such a large amount of data, from people with and without gut conditions, we were able to uncover a pathogenic cell type that may play a role in some chronic conditions and could be a target for intervention in the future. This demonstrates the power of using integrated single-cell atlases in research, and I am confident that applying this approach to other tissues and organs will drive new therapeutic discoveries for a range of conditions.” - Rasa Elmentaite

The Gut Cell Atlas is freely available, and the team has developed new processes to allow future studies to be added, creating an evolving, accessible resource for scientists.

Written By:
Sanger Institute
Image By:
Oliver et al.
Funded By:
Click to read more
×

This work was made possible through collaboration between the Wellcome Sanger Institute, University of Oslo and Oslo University Hospital, IDIBAPS Hospital Clinic Barcelona, Newcastle University, Newcastle University NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, University of Cambridge and the University of Oxford. This work was financially supported by the Wellcome Trust (WT206194 to S.A.T.); the European Research Council (646794, ThDefine to S.A.T.); an MRC New Investigator research grant (MR/T001917/1 to M.Z.); and a project grant from the Great Ormond Street Hospital Children’s Charity, Sparks (V4519 to M.Z.). A.M.C. and V.G. were funded by grant #2008-04050 from The Leona and Harry B. Helmsley Charitable Trust. R.B.-C. was funded by Grant 315307, Researcher Project/International Mobility Grant from the Research Council of Norway, and travel grant from the Per Brandtzæg’s Fund for Research in Mucosal Immunology. E.M.-A. is funded by grant RH042155 (RTI2018-096946-B-I00) from the Ministerio de Ciencia e Innovacion. P.K. is funded by Wellcome grant 222426/Z/21/Z. This study was supported by the NIHR Biomedical Research Centre, Oxford, by grant PID2021-123918OB-I00 from MCIN/AEI/ 10.13039/501100011033 and co-funded by “FEDER A way to make Europe”, Barcelona. A.J.O. is supported by the RESPIRE4 Marie Sklodowska-Curie fellowship (grant agreement 847462). This research was funded in whole, or in part, by the Wellcome Trust (203151/Z/16/Z, 203151/A/16/Z) and the UKRI Medical Research Council (MC_PC_17230).